Previous 10 |
home / stock / aavxf / aavxf news
Abivax ( OTCPK:AAVXF ) announces that the Data Safety Monitoring Board (DSMB) has recommended continuation of its ongoing 12-month extension study, ABX464-102, continuing its completed placebo-controlled Phase 2a induction trial, ABX464-101. More news on: Abivax SA, Healthcare stocks new...
News in focus: NVCR, SGMO Novocure +9.1% after mesothelioma trial shows survival boost Discussion : Novocure ( NVCR ), a midcap biopharma with about $4bn in market capitlization, has seen a tripling of its valuation this year on the back of a slew of positive news. Just about a year a...
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
We're back! I'm your curator, Michael Hopkins. We have some ideas from the biotech side, along with a healthcare REIT. Today, contributors like Brad Thomas , William Meyers , and BZ Equity Research are in the Editors' Picks spotlight. Here are today's Editors' Picks: Long Ideas ...
Introduction HIV therapeutics have undergone a substantial evolution since its inception over three decades ago. From the first controversial FDA-approved drug, Retrovir ((AZT)) to today's newest life-saving combination antiretroviral therapies, HIV therapy has seen incredible progress. Desp...
News, Short Squeeze, Breakout and More Instantly...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with ...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...